The findings address a central problem in cancer immunotherapy. Anti-PD-1 antibodies, often written as αPD1, work by blocking a molecular “brake” that tumors exploit to silence T cells. Under normal conditions, the PD-1 receptor helps prevent excessive immune activity; when it binds to PD-L1 or related ligands on tumor cells and immune cells, it reduces T-cell activation. Drugs that interrupt this interaction can restore the ability of cytotoxic T cells to recognize and destroy malignant cells. Yet most patients do not respond, and even among initial responders, resistance and relapse are common. Researchers have therefore been searching for safe adjuvants—treatments that can make checkpoint blockade more effective without adding substantial toxicity.

The team first screened polysaccharide-rich extracts prepared from six traditional medicines. Polysaccharides are long chains of sugar molecules whose biological effects depend on their precise chemical architecture, including the identity of their component sugars, the bonds connecting them and the branching patterns along the chain. The most promising candidate was Wolfiporia cocos polysaccharide, or WCP. In mice bearing tumors implanted beneath the skin, combining WCP with αPD1 produced stronger tumor control than either treatment alone. The improvement was observed across multiple subcutaneous tumor models, while the researchers found no obvious signs of systemic toxicity under the conditions tested. That distinction is important because many immune-stimulating compounds can cause inflammation throughout the body, potentially limiting their clinical usefulness.

The researchers then asked whether WCP acted directly on tumor cells or required the intestinal microbiome. When the animals’ gut bacteria were depleted, the polysaccharide largely lost its ability to enhance αPD1 therapy. This result suggested that WCP was not simply entering the bloodstream as an intact drug and acting directly on the tumor. Instead, microbes appeared to be processing it into one or more biologically active products. Microbiome analysis identified an increase in the abundance of Turicibacter in animals receiving the combined WCP and αPD1 treatment. The association did not by itself prove that the bacterium caused the therapeutic benefit, but it provided a lead for functional experiments aimed at tracing the chemical transformation.

Those experiments focused on Turicibacter sanguinis and an enzyme linked to a gene or protein designated FUC2. Fucosidases are glycosidases: enzymes that cut the chemical bonds joining fucose residues to larger carbohydrate structures. Fucose is a six-carbon sugar found in many biological glycans, including components of microbial cell surfaces, intestinal mucus and plant- or fungus-derived polysaccharides. The study’s biochemical evidence indicated that FUC2-associated α-L-fucosidase activity could release L-fucose from WCP. In practical terms, the gut bacterium appeared to act as a microscopic processing unit, converting a complex carbohydrate that the mammalian digestive system may not fully break down into a smaller metabolite capable of influencing host immunity.

Several lines of evidence supported this proposed pathway. The investigators used serum metabolomics to survey changes in small molecules circulating through the animals’ blood, then specifically measured L-fucose with targeted assays. They also carried out microbial add-back experiments, reintroducing selected bacteria into microbiota-depleted mice, and engineered Escherichia coli to express the FUC2 enzyme. Supplementing animals with T. sanguinis or with the engineered bacterium partially restored the ability of WCP to improve αPD1 treatment, even after the broader microbial community had been disrupted. Because the rescue was partial rather than complete, the enzyme is unlikely to be the only factor involved. Other microbes, metabolites, immune signals or interactions among bacterial species may also contribute, but the results identify fucosidase-mediated release of L-fucose as a mechanistically testable component.

The immune response inside the tumors offered a second critical piece of evidence. Both WCP and L-fucose increased the accumulation of CD8-positive T cells producing interferon-γ, or IFNγ. These cells are among the immune system’s most effective antitumor agents: after recognizing tumor-associated antigens, they can release cytotoxic molecules and inflammatory signals that damage malignant cells. IFNγ also reshapes the tumor microenvironment by increasing antigen presentation and influencing the behavior of neighboring immune and stromal cells. When the researchers depleted CD8-positive T cells, the antitumor effect disappeared, indicating that the therapeutic benefit was not merely a consequence of slowed tumor growth or a nonspecific metabolic change. It depended on the adaptive immune cells that checkpoint blockade is designed to reactivate.

The study also tested whether WCP could help in a setting meant to mimic treatment-resistant disease. The researchers colonized mice with fecal microbiota obtained from cancer patients who had not responded to immunotherapy. In that context, adding WCP still enhanced αPD1 efficacy. The result is potentially significant because previous research has linked the composition and function of the gut microbiome to checkpoint immunotherapy outcomes. However, a fecal microbiota transfer model is not the same as a human clinical trial. The bacterial communities established in mice may differ from those in their donors, and the animals’ immune systems, diets and tumor models do not reproduce the full complexity of human cancer. The experiment therefore suggests that the polysaccharide may overcome at least some features of a nonresponsive microbial environment, but it does not show that WCP will make anti-PD-1 drugs effective for patients who currently fail to benefit.

The work’s broader implication is that the microbiome may be more than a collection of bacterial species associated with treatment response. Its enzymes could be active determinants of how food-derived or medicinal carbohydrates are converted into immune-modulating molecules. This shifts attention from asking which bacteria are present to asking what biochemical reactions they can perform under particular dietary and therapeutic conditions. A structurally defined polysaccharide such as WCP might eventually be developed as a standardized companion to checkpoint blockade, provided its composition, dose, pharmacology and safety can be established. Before that possibility can be considered clinically, the pathway will need validation in additional models and human samples, along with studies of drug interactions, long-term immune effects and the variability of fucosidase genes across individuals. The authors’ findings nevertheless offer a striking example of how a gut microbial enzyme can unlock the hidden immunological potential of a complex carbohydrate and point toward more personalized combinations of cancer therapy and microbiome-directed treatment.

The team zeroed in on Bacteroides uniformis, a gut bacterium capable of converting the amino acid tryptophan into indole compounds. In mouse models, these indole metabolites were linked to enhanced anti-tumor immunity, resulting in reduced melanoma growth.

To establish causality rather than correlation, researchers used germ-free mice to isolate the effect of this metabolic pathway. Only the indole-producing bacterial strain restored the immune benefits, demonstrating that the tryptophan-to-indole conversion is the critical driver.

When the scientists introduced a genetically modified Bacteroides uniformis that could no longer perform tryptophan degradation into indoles, the protective effect vanished. Tumors then progressed normally, reinforcing the idea that the metabolites themselves—rather than the presence of bacteria alone—shape immune outcomes.

The study also connects the mechanism to human responses. By analyzing samples from cancer patients undergoing immunotherapy, investigators observed elevated levels of enzymes involved in indole production among patients who responded better to treatment.

Together, these findings suggest that indole-producing microbes and their metabolic outputs could serve as biomarkers for immunotherapy responsiveness. More broadly, they point to microbiome-aware strategies that could be engineered through diet, microbial supplementation, or direct delivery of beneficial compounds.

Amanda Ramer-Tait, a professor in Food Science and Technology at UNL, emphasized the promise of identifying a specific microbe-metabolite pair to explain why some patients respond while others do not. Co-leader Ze’ev Ronai highlighted the therapeutic potential of turning these mechanistic insights into future interventions.

Because indoles have roles in modulating immune function beyond melanoma, the approach may extend to other cancer types where immune checkpoint inhibitors are used. The research also notes that work is progressing toward translational applications informed by microbiome metabolism.

Subject of Research: Animals
Article Title: Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth
News Publication Date: 14-Jul-2026
Web References: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00338-1
References: http://dx.doi.org/10.1016/j.xcrm.2026.102921
Image Credits: Craig Chandler/University of Nebraska–Lincoln Communication and Marketing
Keywords: gut microbiome, tryptophan degradation, indole metabolites, Bacteroides uniformis, anti-tumor immunity, melanoma, immunotherapy, germ-free mice

As this challenge persists, researchers have turned their attention to an unconventional yet increasingly pivotal factor influencing cancer immunotherapy outcomes—the gut microbiome. A growing body of evidence underscores the intricate role the gut microbiota plays in modulating immune responses, which in turn affects the therapeutic efficacy of ICIs. Changes in the composition and diversity of gut microbial communities have been correlated with varying responses to immunotherapy, prompting a surge of scientific inquiry into this fascinating biological interplay. Notably, certain bacterial signatures, such as an elevated Clostridiales to Bacteroidales ratio, have been linked with enhanced ICI response, particularly in NSCLC and renal cell carcinoma patients. These findings suggest that the microbiome’s composition is not merely a bystander but an active participant in anti-cancer immunity.

Yet, the gut microbiome is a dynamic ecosystem exquisitely sensitive to numerous external influences. Among these, the concomitant use of various medications emerges as a particularly significant confounder. Antibiotics, proton pump inhibitors (PPIs), and probiotics—drugs commonly administered to cancer patients for diverse indications—exert profound effects on microbial ecology. Antibiotics, by virtue of their broad-spectrum bactericidal actions, can disrupt microbial diversity and eliminate key commensal populations. PPIs, widely used to manage gastrointestinal symptoms, alter gastric pH and subsequently shift microbial populations downstream. Conversely, probiotics aim to modulate or restore microbial balance by supplementing beneficial bacteria, though their precise impact remains under rigorous investigation. The complex interplay between these medications and the microbiome raises important questions regarding their potential to alter ICI outcomes.

Recognizing this pressing need for clarity, a comprehensive meta-analysis led by Xu, Song, Fu, and colleagues synthesized data from 69 studies encompassing 102 cohorts and totaling 22,568 patients to systematically dissect the influence of these drug classes on gut microbiome dynamics and ICI effectiveness. This extensive investigation uniquely integrates clinical outcomes—progression-free survival (PFS), overall survival (OS), and objective response rate (ORR)—to quantify the real-world impact of antibiotics, PPIs, and probiotics on immunotherapy success. Subgroup analyses considering tumor types, timing of drug exposure, and treatment regimens further illuminate nuanced relationships that could guide therapeutic strategies.

The results from the meta-analysis offer a sobering yet insightful perspective. Concurrent administration of antibiotics or PPIs with ICIs consistently correlated with significantly poorer outcomes across OS, PFS, and ORR metrics. This degradation of efficacy underscores the detrimental consequences of disrupting gut microbial balance during critical windows of immune activation. In stark contrast, probiotic supplementation emerged as a potentially beneficial intervention, enhancing ICI responsiveness and suggesting that purposeful modulation of the microbiome could improve therapeutic landscapes. These contrasting findings highlight the delicate equilibrium between microbial communities and host immunity that oncologists must navigate.

Delving deeper, the timing of antibiotic and PPI exposure proved to be a pivotal determinant of clinical impact. Patients receiving antibiotics within a three-month window before or after initiating ICI therapy exhibited strikingly lower OS, PFS, and ORR compared to antibiotic-naïve counterparts. This temporal relationship suggests that early or recent microbiome perturbations impose lasting impairments on immune function relevant to cancer control. Similarly, the negative effects of PPI use were consistent regardless of treatment scheme, reinforcing concerns about their broad and persistent influence on gut ecosystems. This temporal data advocates for clinical vigilance regarding drug scheduling to safeguard microbiome integrity during immunotherapy.

Importantly, these findings propel a paradigm shift towards personalized medicine in oncology. An improved understanding of how common medications modulate the microbiome and, by extension, immunotherapy outcomes empowers clinicians to optimize treatment regimens—not solely focusing on tumor biology but also incorporating microbiome stewardship. Proactive strategies, such as minimizing unnecessary antibiotic or PPI use or judicious incorporation of probiotics, could mitigate adverse microbial influences and enhance patient prognosis. This approach advocates an integrative model of cancer care that appreciates the multifaceted biological systems at play.

Moreover, these insights carry profound implications for future research. The meta-analysis highlights the necessity of incorporating microbiome monitoring and drug exposure histories into clinical trial design. Such integration can unravel mechanistic underpinnings and validate therapeutic interventions aimed at restoring microbial homeostasis. Investigations into specific bacterial taxa and their metabolic products may yield biomarkers predictive of ICI response or targets for microbiome-engineering therapies. As technology advances, precision manipulation of microbial communities could complement immunotherapy, enhancing efficacy and reducing toxicity.

Nonetheless, this study also underscores persistent challenges and knowledge gaps. The heterogeneity in study designs, microbial sequencing methodologies, and clinical variables complicates cross-study comparisons and interpretation. Additionally, factors such as diet, genetic predisposition, and environmental exposures further modulate the microbiome but require more systematic investigation. Addressing these complexities demands interdisciplinary collaboration across oncology, microbiology, immunology, and pharmacology to fully harness the microbiome’s therapeutic potential.

In conclusion, the meta-analysis by Xu and colleagues offers a critical, data-driven synthesis that advances our understanding of how commonly used drugs influence the gut microbiome and, consequently, the efficacy of cancer immunotherapies. Their work galvanizes attention towards more holistic patient management strategies that integrate microbiome considerations alongside conventional oncologic care. By untangling the intricate web of drug-microbiome-host interactions, this research paves the way for more personalized, effective, and safer immunotherapy regimens that stand to profoundly improve outcomes in oncology.

As cancer immunotherapy continues to evolve as a transformative treatment paradigm, these findings emphasize the importance of preserving and harnessing the gut microbiome’s beneficial roles. Future clinical guidelines will likely incorporate recommendations regarding antibiotic stewardship, PPI cautiousness, and probiotic use, potentially accompanied by microbiome profiling in routine practice. As researchers delve deeper into this burgeoning field, the synergistic interface of microbiome science and immunotherapy holds promise not only for enhancing response rates but also for expanding the frontiers of cancer care in the coming decades.

Subject of Research: The impact of concomitant drug use (antibiotics, proton pump inhibitors, and probiotics) on gut microbiome dynamics and their influence on the efficacy of immune checkpoint inhibitor (ICI) cancer immunotherapy.

Article Title: Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects

Article References:
Xu, J., Song, J., Fu, Z. et al. Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects. BMC Cancer 25, 1776 (2025). https://doi.org/10.1186/s12885-025-15094-9

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15094-9 (Published 17 November 2025)